<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00843479</url>
  </required_header>
  <id_info>
    <org_study_id>LIMED0006</org_study_id>
    <nct_id>NCT00843479</nct_id>
  </id_info>
  <brief_title>The Aging Endocrine Pancreas: Characterization of the Entero-insular Axis Physiology in the Elderly</brief_title>
  <official_title>The Aging Endocrine Pancreas: Characterization of the Entero-insular Axis Physiology in the Elderly.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campinas, Brazil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Like most endocrine axes, the entero-insular axis is expected to go through an age-related
      physiological deterioration, what might contribute to special features of the elderly onset
      type 2 diabetes in comparison to middle-age.

      Twenty four NGT volunteers will be evaluated by a meal tolerance test (MTT) for incretin
      hormone measurements, and by the hyperglycemic clamp followed by an arginine test for
      assessing the beta-cell function and the acute insulin response. Others parameters as body
      composition and basic biochemistry will be also evaluated at Laboratory of Investigation on
      Metabolism and Diabetes - LIMED / State university of Campinas, Brazil.

      The characterization of the glucagon-like peptide-1 (GLP-1) production, dipeptidyl peptidase
      IV (DPP-IV) activity and/or endocrine pancreas incretin-response at aging, might be an
      interesting evidence to reinforce an incretin-based therapeutic approach for elderly onset
      type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Homeostasis Model Assessment Insulin Resistance (HOMA-IR) Index</measure>
    <time_frame>within 1 month from screening visit</time_frame>
    <description>Insulin sensitivity index calculated as HOMA-IR = (Glucose * Insulin) / 22.5, where glucose is mmol/L and insulin is mili-units (mU)/L. Higher values indicate lower insulin sensitivity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose Infusion Rate</measure>
    <time_frame>within 1 month from screening visit</time_frame>
    <description>Whole-body insulin sensitivity, as estimated by the mean glucose infusion rate corrected for fat-free mass(FFM){mg*[kg(FFM)^-1]*min*10} at last 60 min of 180-min hyperglycemic clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adaptive Beta-cell Insulin Production. The Product of Meal Tolerance Test-derived Insulinogenic Index (IGI) for Clamp-derived Insulin Sensitivity Index (ISI) in Normoglycemic Subjects After 65 Years Old in Comparison With Middle-age Normoglycemic Subjects</measure>
    <time_frame>within 1 month from screening visit</time_frame>
    <description>Beta-cell function was determinated as the beta-cell secretion measured by meal tolerance test adjusted by insulin sensitivity assessed by the hyperglycemic clamp test:Insulinogenic Index/Insulin Sensitivity Index adjusted by free fat mass</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distinctive Beta-cell Function From the Arginine Stimulation Test in Normoglycemic Subjects After Sixty-five Years Old in Comparison With Middle-age Normoglycemic Subjects.</measure>
    <time_frame>within 1 month from screening visit</time_frame>
    <description>Distinctive beta-cell function as measured by the disposition index - based on the acute insulin response from the arginine stimulation test versus glucose infusion rate adjusted by free fat mass from hyperglycemic clamp - in normoglycemic subjects after sixty-five years old in comparison with middle-age normoglycemic subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Dipeptidyl Peptidase IV (DPP-IV) Concentration</measure>
    <time_frame>within 1 month from screening visit</time_frame>
    <description>measured in fasting serum sample by ELISA kit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GLP-1 Area Under the Curve (AUC)</measure>
    <time_frame>1 month from screening visit</time_frame>
    <description>Area under the curve of glucagon-like peptide (GLP-1) concentrations (measured by ELISA kit) from time 0 to 180 min during a standard meal tolerance test, calculated by the trapezoidal rule.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Elderly NGT</arm_group_label>
    <description>Normoglycemic subjects 65-80 years old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle-age NGT</arm_group_label>
    <description>Middle-age normoglycemic subjects 35 to 50 years old.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Sera and plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult normoglycemic subjects
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable weight (&lt; 5% variation) within the last three months

          -  Age: 35 to 50 years old for middle-age group, and 65 to 80 years old for elderly
             group.

          -  BMI: 20 to 29.9 kg/m2

          -  Normal glucose tolerance (NGT) for groups Elderly and Middle-age

        Exclusion Criteria:

          -  Use of estrogen, progestogen or systemic corticosteroids.

          -  Hepatic cirrhosis, renal failure or any clinical condition with impaired insulin
             sensitivity

          -  Smoking

          -  Obesity

          -  Uncontrolled systemic or debilitating diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Geloneze, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LIMED (Laboratory of Investigation of Metabolism and Diabetes)/GASTROCENTRO/Univeristy of Campinas (UNICAMP)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LIMED (Laboratory of Investigation of Metabolism and Diabetes)/GASTROCENTRO/Univeristy of Campinas (UNICAMP)</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2009</study_first_submitted>
  <study_first_submitted_qc>February 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2009</study_first_posted>
  <results_first_submitted>October 4, 2011</results_first_submitted>
  <results_first_submitted_qc>March 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 22, 2013</results_first_posted>
  <last_update_submitted>March 7, 2013</last_update_submitted>
  <last_update_submitted_qc>March 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campinas, Brazil</investigator_affiliation>
    <investigator_full_name>Bruno Geloneze</investigator_full_name>
    <investigator_title>Dr. Bruno Geloneze</investigator_title>
  </responsible_party>
  <keyword>diabetes mellitus, type 2</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Aging</keyword>
  <keyword>Incretins</keyword>
  <keyword>DPP-IV protein, human</keyword>
  <keyword>Glucagon-Like Peptide 1</keyword>
  <keyword>Gastric Inhibitory Polypeptide</keyword>
  <keyword>insulin</keyword>
  <keyword>glucagon</keyword>
  <keyword>ghrelin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment process took place at the Laboratory of Investigation on Metabolism and Diabetes - LIMED, located at the Medical School of the State University of Campinas (UNICAMP).</recruitment_details>
      <pre_assignment_details>Cross-sectional study conducted with 24 non-obese patients with normal glucose tolerance. Two groups formed: middle-aged (n=12) and aged(n=12). They were healthy and had no significant illness. None were taking drugs that affect insulin sensitivity/secretion or incretin hormones.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Elderly Normal Glucose Tolerance (NGT)</title>
          <description>Normoglycemic subjects 65-80 years old</description>
        </group>
        <group group_id="P2">
          <title>Middle-age Normal Glucose Tolerance (NGT)</title>
          <description>Middle-age normoglycemic subjects 35 to 50 years old.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Elderly Normal Glucose Tolerance (NGT)</title>
          <description>Normoglycemic subjects 65-80 years old</description>
        </group>
        <group group_id="B2">
          <title>Middle-age Normal Glucose Tolerance (NGT)</title>
          <description>Middle-age normoglycemic subjects 35 to 50 years old.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0"/>
                    <measurement group_id="B2" value="0" spread="0"/>
                    <measurement group_id="B3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0"/>
                    <measurement group_id="B2" value="12" spread="0"/>
                    <measurement group_id="B3" value="12" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12" spread="0"/>
                    <measurement group_id="B2" value="0" spread="0"/>
                    <measurement group_id="B3" value="12" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="2"/>
                    <measurement group_id="B2" value="44" spread="4"/>
                    <measurement group_id="B3" value="54" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Homeostasis Model Assessment Insulin Resistance (HOMA-IR) Index</title>
        <description>Insulin sensitivity index calculated as HOMA-IR = (Glucose * Insulin) / 22.5, where glucose is mmol/L and insulin is mili-units (mU)/L. Higher values indicate lower insulin sensitivity.</description>
        <time_frame>within 1 month from screening visit</time_frame>
        <population>minimum number required to find a significant difference between groups considering the intra-subject variation</population>
        <group_list>
          <group group_id="O1">
            <title>Elderly Normal Glucose Tolerance (NGT)</title>
            <description>Normoglycemic subjects 65-80 years old</description>
          </group>
          <group group_id="O2">
            <title>Middle-age Normal Glucose Tolerance (NGT)</title>
            <description>Middle-age normoglycemic subjects 35 to 50 years old.</description>
          </group>
        </group_list>
        <measure>
          <title>Homeostasis Model Assessment Insulin Resistance (HOMA-IR) Index</title>
          <description>Insulin sensitivity index calculated as HOMA-IR = (Glucose * Insulin) / 22.5, where glucose is mmol/L and insulin is mili-units (mU)/L. Higher values indicate lower insulin sensitivity.</description>
          <population>minimum number required to find a significant difference between groups considering the intra-subject variation</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" spread="1.0"/>
                    <measurement group_id="O2" value="0.84" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.07</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Glucose Infusion Rate</title>
        <description>Whole-body insulin sensitivity, as estimated by the mean glucose infusion rate corrected for fat-free mass(FFM){mg*[kg(FFM)^-1]*min*10} at last 60 min of 180-min hyperglycemic clamp</description>
        <time_frame>within 1 month from screening visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Elderly Normal Glucose Tolerance (NGT)</title>
            <description>Normoglycemic subjects 65-80 years old</description>
          </group>
          <group group_id="O2">
            <title>Middle-age Normal Glucose Tolerance (NGT)</title>
            <description>Middle-age normoglycemic subjects 35 to 50 years old.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Infusion Rate</title>
          <description>Whole-body insulin sensitivity, as estimated by the mean glucose infusion rate corrected for fat-free mass(FFM){mg*[kg(FFM)^-1]*min*10} at last 60 min of 180-min hyperglycemic clamp</description>
          <units>mg*[kg(FFM)^-1]*min*10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.16"/>
                    <measurement group_id="O2" value="1.73" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adaptive Beta-cell Insulin Production. The Product of Meal Tolerance Test-derived Insulinogenic Index (IGI) for Clamp-derived Insulin Sensitivity Index (ISI) in Normoglycemic Subjects After 65 Years Old in Comparison With Middle-age Normoglycemic Subjects</title>
        <description>Beta-cell function was determinated as the beta-cell secretion measured by meal tolerance test adjusted by insulin sensitivity assessed by the hyperglycemic clamp test:Insulinogenic Index/Insulin Sensitivity Index adjusted by free fat mass</description>
        <time_frame>within 1 month from screening visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Elderly Normal Glucose Tolerance (NGT)</title>
            <description>Normoglycemic subjects 65-80 years old</description>
          </group>
          <group group_id="O2">
            <title>Middle-age Normal Glucose Tolerance (NGT)</title>
            <description>Middle-age normoglycemic subjects 35 to 50 years old.</description>
          </group>
        </group_list>
        <measure>
          <title>Adaptive Beta-cell Insulin Production. The Product of Meal Tolerance Test-derived Insulinogenic Index (IGI) for Clamp-derived Insulin Sensitivity Index (ISI) in Normoglycemic Subjects After 65 Years Old in Comparison With Middle-age Normoglycemic Subjects</title>
          <description>Beta-cell function was determinated as the beta-cell secretion measured by meal tolerance test adjusted by insulin sensitivity assessed by the hyperglycemic clamp test:Insulinogenic Index/Insulin Sensitivity Index adjusted by free fat mass</description>
          <units>(μmol∙kg-1min-1)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.9"/>
                    <measurement group_id="O2" value="3.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Distinctive Beta-cell Function From the Arginine Stimulation Test in Normoglycemic Subjects After Sixty-five Years Old in Comparison With Middle-age Normoglycemic Subjects.</title>
        <description>Distinctive beta-cell function as measured by the disposition index - based on the acute insulin response from the arginine stimulation test versus glucose infusion rate adjusted by free fat mass from hyperglycemic clamp - in normoglycemic subjects after sixty-five years old in comparison with middle-age normoglycemic subjects.</description>
        <time_frame>within 1 month from screening visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Elderly NGT</title>
            <description>Normoglycemic subjects 65-80 years old</description>
          </group>
          <group group_id="O2">
            <title>Middle-age NGT</title>
            <description>Middle-age normoglycemic subjects 35 to 50 years old</description>
          </group>
        </group_list>
        <measure>
          <title>Distinctive Beta-cell Function From the Arginine Stimulation Test in Normoglycemic Subjects After Sixty-five Years Old in Comparison With Middle-age Normoglycemic Subjects.</title>
          <description>Distinctive beta-cell function as measured by the disposition index - based on the acute insulin response from the arginine stimulation test versus glucose infusion rate adjusted by free fat mass from hyperglycemic clamp - in normoglycemic subjects after sixty-five years old in comparison with middle-age normoglycemic subjects.</description>
          <units>(μmol∙kg-1.min-1)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328.5" spread="303.4"/>
                    <measurement group_id="O2" value="223.5" spread="174.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Dipeptidyl Peptidase IV (DPP-IV) Concentration</title>
        <description>measured in fasting serum sample by ELISA kit</description>
        <time_frame>within 1 month from screening visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Elderly Normal Glucose Tolerance (NGT)</title>
            <description>Normoglycemic subjects 65-80 years old</description>
          </group>
          <group group_id="O2">
            <title>Middle-age Normal Glucose Tolerance (NGT)</title>
            <description>Middle-age normoglycemic subjects 35 to 50 years old.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Dipeptidyl Peptidase IV (DPP-IV) Concentration</title>
          <description>measured in fasting serum sample by ELISA kit</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1466.6" spread="1088.8"/>
                    <measurement group_id="O2" value="1458.2" spread="1006.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GLP-1 Area Under the Curve (AUC)</title>
        <description>Area under the curve of glucagon-like peptide (GLP-1) concentrations (measured by ELISA kit) from time 0 to 180 min during a standard meal tolerance test, calculated by the trapezoidal rule.</description>
        <time_frame>1 month from screening visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Elderly Normal Glucose Tolerance (NGT)</title>
            <description>Normoglycemic subjects 65-80 years old</description>
          </group>
          <group group_id="O2">
            <title>Middle-age Normal Glucose Tolerance (NGT)</title>
            <description>Middle-age normoglycemic subjects 35 to 50 years old.</description>
          </group>
        </group_list>
        <measure>
          <title>GLP-1 Area Under the Curve (AUC)</title>
          <description>Area under the curve of glucagon-like peptide (GLP-1) concentrations (measured by ELISA kit) from time 0 to 180 min during a standard meal tolerance test, calculated by the trapezoidal rule.</description>
          <units>pg/ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1061.7" spread="354.4"/>
                    <measurement group_id="O2" value="1027.1" spread="164.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Elderly Normal Glucose Tolerance (NGT)</title>
          <description>Normoglycemic subjects 65-80 years old</description>
        </group>
        <group group_id="E2">
          <title>Middle-age Normal Glucose Tolerance (NGT)</title>
          <description>Middle-age normoglycemic subjects 35 to 50 years old.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bruno Geloneze</name_or_title>
      <organization>Laboratory of Investigation on Metabolism and Diabetes - LIMED / State University of Campinas - Brazil</organization>
      <phone>+55 19 35218589</phone>
      <email>bgeloneze@terra.com.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

